Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sonus Pharma (SNUS) ? Opinions -- Ignore unavailable to you. Want to Upgrade?

To: David S. who wrote (213)	2/5/1998 9:45:00 PM
From: Raptor	Read Replies (1) \| Respond to of 384

I haven't been around this board much before, but I gotta agree with Dale. Blanket statements, unsubstantiated by any data or facts, intended to show just how smart you are compared to everybody, are not very mature. I know, I used to do that kind of stuff too. Before I realized it wasn't all about beating everybody else, but about sharing and debating the merits. So David, oh wise one, if you like to add some light to our discussion, rather than vainly work the short side, please do. Otherwise, your scare tactics ring a bit hollow. Perhaps you should return to the Iomega board.

To: David S. who wrote (213)	2/5/1998 10:04:00 PM
From: Raptor	Read Replies (1) \| Respond to of 384

Sorry for the double post, but in the interest of discussing the merits...some have said that "if SNUS loses the patent case, it has further to fall" or words to that effect. My understanding of the patent situation is that the patent office is in the process of ruling on the validity of several patents in this area, including two from SNUS. Outcome uncertain. At the same time, SNUS has filed a lawsuit against MB claiming infringement of these two patents. At this time, MB has no pending lawsuits against SNUS. The suit thrown out from the DC District court for jurisdictional reasons was filed by MB for the express purpose of preventing SNUS from filing its infringement suit. Now that the suit has been filed, MB has no reason to refile. MB has made some vague comments about future action against SNUS, but there seems to be no basis for it. MB's primary patents cover the coating used to cover the gas microbubbles. SNUS uses an entirely different method, which does not use the same albumen coating. So, if everybody's patents are overturned, all it means is they compete in the marketplace. That is a win win for both companies. If SNUS wins the patent case, sayonara MB. Just my take..